Cologuard: not Exact enough?
This article was originally published in Clinica
Executive Summary
Exact Sciences’ share price took a beating last week after a pivotal study of its Cologuard colorectal cancer screening test met its primary and secondary endpoints, but fell short on the detection of precancerous polyps. The stool-based DNA test looks for mutations associated with cancer and precancerous conditions, and is based on the principle that cancers and polyps shed cells into the stool stream.